Dr Abraham discussed the best application of integrins for management of inflammatory bowel diseases for management of inflammatory bowel diseases at the Advances in Inflammatory Bowel Diseases virtual regional meeting on June 19.

Bincy Abraham, MD, is a professor of medicine at Houston Methodist Weill Cornell Medical School in Houston, Texas.

TRANSCRIPT

During this conference, I presented on the optimal use of integrins for the management of inflammatory bowel disease. The key takeaways on this included appropriate patient selection based on their severity and location of their disease, their comorbidities and concomitant diseases, and patient preferences.

I provided information on optimal positioning in ulcerative colitis based on our first-ever head-to-head VARSITY trial that evaluated the efficacy and safety of vedolizumab compared to adalimumab as well as real-world data from the VICTORY Consortium. I also evaluated our AGA guidelines and network meta-analysis on where to place vedolizumab in treating ulcerative colitis.

For Crohn's disease, I discussed the GEMINI clinical trials, the data efficacy and safety from them, network meta-analysis, as well as evidence from real world through the VICTORY Consortium in the compared effectiveness data that they provided. I then ended with some input on early vedolizumab trough levels that could predict later response.

With this presentation, I hope that you're able to get an understanding of clinically how to optimize the use of integrins in your management of your IBD patients.